Advertisement
UK markets close in 5 hours 41 minutes
  • FTSE 100

    8,052.09
    +28.22 (+0.35%)
     
  • FTSE 250

    19,683.41
    +84.02 (+0.43%)
     
  • AIM

    752.18
    +3.00 (+0.40%)
     
  • GBP/EUR

    1.1593
    +0.0004 (+0.03%)
     
  • GBP/USD

    1.2358
    +0.0007 (+0.06%)
     
  • Bitcoin GBP

    53,540.19
    +190.98 (+0.36%)
     
  • CMC Crypto 200

    1,423.13
    +8.37 (+0.59%)
     
  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     
  • DOW

    38,239.98
    +253.58 (+0.67%)
     
  • CRUDE OIL

    82.14
    +0.24 (+0.29%)
     
  • GOLD FUTURES

    2,311.30
    -35.10 (-1.50%)
     
  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     
  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     
  • DAX

    17,988.58
    +127.78 (+0.72%)
     
  • CAC 40

    8,069.80
    +29.44 (+0.37%)
     

Those who invested in Boston Scientific (NYSE:BSX) five years ago are up 72%

Generally speaking the aim of active stock picking is to find companies that provide returns that are superior to the market average. And the truth is, you can make significant gains if you buy good quality businesses at the right price. For example, long term Boston Scientific Corporation (NYSE:BSX) shareholders have enjoyed a 72% share price rise over the last half decade, well in excess of the market return of around 41% (not including dividends). On the other hand, the more recent gains haven't been so impressive, with shareholders gaining just 24%.

With that in mind, it's worth seeing if the company's underlying fundamentals have been the driver of long term performance, or if there are some discrepancies.

Check out our latest analysis for Boston Scientific

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

ADVERTISEMENT

Over half a decade, Boston Scientific managed to grow its earnings per share at 48% a year. The EPS growth is more impressive than the yearly share price gain of 11% over the same period. So it seems the market isn't so enthusiastic about the stock these days. Having said that, the market is still optimistic, given the P/E ratio of 88.35.

The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

We know that Boston Scientific has improved its bottom line lately, but is it going to grow revenue? You could check out this free report showing analyst revenue forecasts.

A Different Perspective

We're pleased to report that Boston Scientific shareholders have received a total shareholder return of 24% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 11% per year), it would seem that the stock's performance has improved in recent times. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Boston Scientific better, we need to consider many other factors. For instance, we've identified 3 warning signs for Boston Scientific (1 is significant) that you should be aware of.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here